α-SYNUCLEIN EXPRESSION INHIBITOR

WIPO Patent Application WO/2019/009298

A1

According to the present invention, a nucleic acid medicine, which has a higher effect of inhibiting α-synuclein expression and sustains this effect for a longer period of time, can be provided. The oligonucleotide according to the present invention or a pharmacologically acceptable salt thereof is characterized by: containing at least one nucleoside structure represented by formula (I) [wherein each of "Base" and "A" represents a definite substituent or structure]; being capable of binding to an α-synuclein gene; having an activity of inhibiting the expression of the α-synuclein gene; being complementary to the α-synuclein gene; having a specific sequence; being complementary to at least a part of α-synuclein represented by SEQ ID NO: 1; and having an oligonucleotide length of 12-20 bases.

NAKAMORI MASAYUKI (JP)
MOCHIZUKI HIDEKI (JP)
OBIKA SATOSHI (JP)
KASAHARA YUYA (JP)
KOIZUMI MAKOTO (JP)
NAKAMURA AKIFUMI (JP)
TAKAISHI KIYOSUMI (JP)
ASAHI YUMIKO (JP)

PCT/JP2018/025236

January 10, 2019

July 03, 2018

Click for automatic bibliography generation  

UNIV OSAKA (JP)
NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION (JP)
DAIICHI SANKYO CO LTD (JP)

C12N15/113; A61K31/712; A61P25/16; A61P25/28

WO2011052436A1	2011-05-05
WO2015125783A1	2015-08-27
WO2014046212A1	2014-03-27
WO2016017422A1	2016-02-04
WO2017119463A1	2017-07-13

JP2014501507A	2014-01-23
JP2007528367A	2007-10-11
JP2015536927A	2015-12-24
JP2011155914A	2011-08-18
JP2002516256A	2002-06-04

HARI ET AL.: "Synthesis of oligo-nucleic acid including novel six-membered rings cross-linked thymidine and evaluation of fuction", 2014

UEKI, Kyuichi et al. (JP)

View/Download PDF      PDF Help

Previous Patent: ANALYSIS SYSTEM, ANALYSIS METHOD, PROGRAM, AND STORAGE MEDIUM

Next Patent: ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF α-SYNUCLEIN EXPRESSION